40775-75-5

Usage

Uses

Used in Pharmaceutical Industry:
5-Hydroxy-[1,2,4]triazolo[1,5-a]pyrimidin-7-ol is used as a key intermediate in the synthesis of aralkyl amine-based triazolopyrimidine inhibitors. These inhibitors exhibit potent antimalarial activity and are being developed for the treatment of malaria.
Additionally, 7-Hydroxy-[1,2,4]triazolo[1,5-a]pyrimidin-5(1H)-one, a related compound, is also used in the synthesis of aralkyl amine-based triazolopyrimidine inhibitors for malaria treatment and antimalarial activity. This highlights the significance of the triazolopyrimidine framework in developing new therapeutic agents to combat malaria.

InChI:InChI=1/C5H4N4O2/c10-3-1-4(11)9-5(8-3)6-2-7-9/h1-2,11H,(H,6,7,8,10)

Upstream product

• 7170-01-6 5-methyl-1H-1,2,4-triazole 
• 105-53-3 diethyl malonate 
• 61-82-5 3-amino-1,2,4-triazole 
• 61-82-5 3⁽⁵⁾-amino-1,2,4-triazole 

Downstream Products

• 78706-26-0 5,7-Dichlor-1,2,4-triazolo<1,5-a>pyrimidin 
• 1469868-37-8 4-(5-(2,6-dimethylphenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 
• 1469868-41-4 4-(5-(mesityloxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 
• 1469868-39-0 4-(5-(4-bromo-2,6-dimethylphenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 
• 1469868-38-9 4-(5-(2,4,6-trichlorophenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 
• 1469868-40-3 4-(5-(2,4,6-trifluorophenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-7-yl)aminobenzonitrile 
• 1469868-42-5 4-((7-(2,6-dimethylphenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)amino)benzonitrile 
• 1469868-46-9 4-((7-(2,6-dichlorophenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)amino)benzonitrile 
• 1469868-45-8 4-((7-(mesityloxy)-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)amino)benzonitrile 
• 1469868-48-1 7-(mesityloxy)-N-(4-nitrophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-5-amine 
• 1469868-49-2 N-(4-chlorophenyl)-7-(mesityloxy)-[1,2,4]triazolo[1,5-a]pyrimidin-5-amine 
• 1469868-51-6 7-(mesityloxy)-N-(p-tolyl)-[1,2,4]triazolo[1,5-a]pyrimidin-5-amine 
• 1469868-54-9 7-(mesityloxy)-N-(4-methoxyphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-5-amine 
• 1469868-43-6 4-((7-(4-bromo-2,6-dimethylphenoxy)-[1,2,4]triazolo[1,5-a]pyrimidin-5-yl)amino)benzonitrile 

Relevant academic research and scientific papers

BCL6-targeting aromatic ring five-membered aromatic heterocyclic micromolecular organic compound and derivative and application thereof

The invention discloses an aromatic ring five-membered aromatic heterocyclic micromolecular organic compound or related analogues or pharmaceutically acceptable salts thereof. The structures of the compound are shown as formulas (I-IX). The invention also

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: Optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches

In our arduous efforts to develop new potent HIV-1 non-nucleoside reverse transcriptase (RT) inhibitors (NNRTIs), novel piperidine-linked [1,2,4]triazolo[1,5-a]pyrimidine derivatives were designed, synthesized and evaluated for their antiviral activities

Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: Discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach

Guided by crystal structures of HIV-1 RT/DAPY complex and molecular modeling studies, a series of novel [1,2,4]triazolo[1,5-a]pyrimidine derivatives were rationally designed via structure-based core refining approach, synthesized through the readily acces

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice

Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance.We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF5-Ph and 3,5-Di-F-4- CF 3-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.